CLINICAL AND FUNCTIONAL FEATURES AND BRONCHOPROTECTIVE EFFECT OF M-CHOLINOLITHICS IN PATIENTS WITH COPD WITH BRONCHIAL HYPERREACTIVITY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bronchial hyperreactivity (BHR) is one of the pathophysiological characteristics of chronic obstructive pulmonary disease (COPD) and is observed in most patients with this disease. Epidemiological studies, incl. recently conducted, demonstrate that ВНР is an independent predictor of COPD development. The available scientific evidence indicates a negative modifying effect of ВНР on the course of COPD. ВНР in COPD is associated with more severe respiratory symptoms, frequent exacerbations of the disease, decreased quality of life, rapidly progressing obstructive disorders, and a higher mortality rate. In this regard, ВНР in COPD appears to be an extremely important therapeutic target, and a decrease in ВНР levels has a significant clinical effect on the course of the disease. Thus, ВНР should be considered not only as a risk factor for developing COPD and a marker of unfavorable prognosis, but also as an indicator that determines the variability of clinical manifestations and the therapeutic response.

Full Text

Restricted Access

About the authors

I. N Trofimenko

Irkutsk State Medical Academy of Postgraduate Education a Branch of FSBEl FPE RMACPE of RMH

Email: tin11@mail.ru
MD, Associate Professor at the Department of Clinical Allergology and Pulmonology

B. A Chernyak

Irkutsk State Medical Academy of Postgraduate Education a Branch of FSBEl FPE RMACPE of RMH

Email: tin11@mail.ru
Department of Clinical Allergology and Pulmonology

References

  1. Barnes P.J. Mechanisms in COPD. Differences from asthma. Chest. 2000; 117:10-4.
  2. Айсанов 3.P., Калманова E.H. Исследование респираторной функции при хронической обструктивной болезни легких. Хроническая обструктивная болезнь легких / Под ред. А.Г. Чучалина. М., 2008. С. 217-30.
  3. Schwartz J., Schindler C., Zemp E., Perruchoud A.P., Zellweger J.P, Wuthrich B., Leuenberger P., Ackermann-Liebrich U. Predictors of methacholine responsiveness in a general population. Chest. 2002;122(3):812-20.
  4. Приходько А.Г., Перельман Ю.М., Колосов B. П. Гиперреактивность дыхательных путей. Владивосток, 2011. 204 с.
  5. Curjuric I., Zemp E., Dratva J., Ackermann-Liebrich U., Bridevaux P-О., Bettschart R. W., Brutsche M., Frey M., Gerbase M.W., Knopfli B., Kunzli N., Pons M., Schwartz J., Schindler C., Rochat T. Determinants of change in airway reactivity over 11 years in the SAPALDIA population study. Eur. Respir. J. 2011 ;37(3):492-500.
  6. Kanner R.E., Connett J. E., Altose M.D., Buist A.S., Lee W.W., Tashkin D.P., Wise R.A. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am. J. Respir. Crit. Care Med. 1994; 150(4):956-61.
  7. Yang S.C., Lin B.Y. Comparison of Airway Hyperreactivity in Chronic Obstructive Pulmonary Disease and Asthma. Chang Gung Med. J. 2010;33:515-23.
  8. Трофименко И. H., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология. 2011 ; 4:49-53.
  9. Dosman J.A., Gomez S.R., Zhou C. Relationship between airways responsiveness and the development of chronic obstructive pulmonary disease. Med. Clin. North. Am. 1990;74(3):561 -69.
  10. Van Schayck C.P., Dompeling E., Molema J., Folgering H., van Grunsven P.M., van Weel C. Does bronchial hyperresponsiveness precede or follow airway obstruction in asthma or COPD? Neth.J. Med. 1994;45(4):145-53.
  11. De Marco R., Accordini S., Marcon A., Cerveri I., Anto J.M., Gislason T., Heinrich J., Janson C., Jarvis D., Kuenzli N., Leynaert B., Sunyer J., Svanes C., Wjst M., Burney P. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011 ;183(7):891-97.
  12. Traulsen L.K., Baelum J., Halling A., Thomsen G., Thilsing T., Sherson D., Sigsgaard T., Omland Q., Mailing T., Skadhauge L.R. Risk factors for incident asthma and COPD in a cohort of young adults. Clin. Respir. J. 2017;7.
  13. O'Connor G., Sparrow D., Weiss S. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. Am. J. Respir. Crit. Care Med. 1995;152:87-92.
  14. Postma D.S., Kerstjens H.A. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998;158:187-92.
  15. Ten Hacken N.H., Postma D.S., Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr. Opin. Pulm. Med. 2003;9:9-14.
  16. Zanini A., Cherubino F., Zampogna E., Croce S., Pignatti P., Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstruc-tive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 1155-61.
  17. Трофименко И.H., Черняк Б.А. Предикторы тяжелой одышки у больных хронической обструктивной болезнью легких средней степени тяжести. Пульмонология. 2014;2:55-9.
  18. Черняк Б.А., Трофименко И.Н. Бронхопротективный эффект тиотропия при хронической обструктивной болезни легких. Фарматека. 2012;15:75-80.
  19. Трофименко И.H., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Иркутск, 2014. 148 с.
  20. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. www.goldcopd.org
  21. Kohlhaufl M., Brand P., Scheuch G., Meyer T.S., Schulz H., Haussinger K., Heyder J. Increased fine particle deposition in women with asymptomatic nonspecific airway hyperresponsiveness. Am. J. Respir. Crit. Care. Med. 1999;159:902-6.
  22. Hospers JJ., Postma D.S., Rijcken B., Weiss S.T., Schouten J.P. Histamine airway hyperresponsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356:1313-17.
  23. Айсанов 3.P., Авдеев C.H., Архипов В.В., Белевский A.C., Лещенко И.В., Овчаренко С.И., Шмелев Е.И., Чучалин А.Г. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клиниче ских решений. Пульмонология. 2017; 1:13-20.
  24. Deesomchok A., Webb K.A., Forkert L., Lam Y.M., Ofir D., Jensen D., O'Donnell D.E. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD. 2010;7(6):428-37.
  25. Santus P., Radovanovic D., Henchi S., DiMarco F., Centanni S., D'Angelo E., Pecchiari M. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol. 2014;15: 36-45.
  26. Neziri B., Dad A., Krasniqi S., Sopi R., Haxhiu M.A. The impact of bilateral vagotomy on the physostigmine-induced airway constriction in ferrets. Respir. Physiol. Neurobiol. 2017;242:102-7.
  27. Montuschi P., Macagno F., Valente S., Fuso L. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr. Med. Chem. 2013;20(12):1464-76.
  28. Barnes P.J. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. 2004;117:24-32.
  29. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005;2:297-304.
  30. Matera M.G., Rogliani P., Cazzola M. Muscarinic receptor antagonists for the treat-ment of chronic obstructive pulmonary disease. Expert. Opin. Pharmacother. 2014;15(7):961-77.
  31. Buels K.S., Fryer A.D. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol. 2012;208: 317-41.
  32. O'Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-80.
  33. Blais C.M., Davis B.E., Cockcroft D.W. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med. 2016;118:96-101.
  34. Tashkin D.P., Celli В., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M.A. 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008;359(15): 1543-54.
  35. Chapman K.R., Beeh K.M., Beier J., Bateman E.D., D'Urzo A., Nutbrown R.f Henley M., Chen H., Overend T., D'Andrea P. A blinded evaluation of the efficacy and safety of gly-copyrronium, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC. Pulm. Med. 2014; 14:4

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies